CN105246460A - 消旋卡多曲类脂组合物 - Google Patents

消旋卡多曲类脂组合物 Download PDF

Info

Publication number
CN105246460A
CN105246460A CN201480015975.XA CN201480015975A CN105246460A CN 105246460 A CN105246460 A CN 105246460A CN 201480015975 A CN201480015975 A CN 201480015975A CN 105246460 A CN105246460 A CN 105246460A
Authority
CN
China
Prior art keywords
composition
weight
oil
racecadotril
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480015975.XA
Other languages
English (en)
Chinese (zh)
Inventor
D-Y.李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenvue Brands LLC
Original Assignee
Johnson and Johnson Consumer Companies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Consumer Companies LLC filed Critical Johnson and Johnson Consumer Companies LLC
Publication of CN105246460A publication Critical patent/CN105246460A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480015975.XA 2013-03-15 2014-03-12 消旋卡多曲类脂组合物 Pending CN105246460A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787597P 2013-03-15 2013-03-15
US61/787597 2013-03-15
PCT/US2014/023903 WO2014150660A1 (en) 2013-03-15 2014-03-12 Racecadotril lipid compositions

Publications (1)

Publication Number Publication Date
CN105246460A true CN105246460A (zh) 2016-01-13

Family

ID=50628914

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480015975.XA Pending CN105246460A (zh) 2013-03-15 2014-03-12 消旋卡多曲类脂组合物

Country Status (15)

Country Link
US (2) US9801819B2 (enExample)
EP (1) EP2968138B1 (enExample)
JP (1) JP2016512828A (enExample)
KR (1) KR20160101167A (enExample)
CN (1) CN105246460A (enExample)
AU (2) AU2014235733B2 (enExample)
BR (1) BR112015023387A2 (enExample)
CA (2) CA2907195A1 (enExample)
IL (1) IL241065A0 (enExample)
MX (2) MX2015012345A (enExample)
PH (1) PH12015502014A1 (enExample)
RU (2) RU2662069C2 (enExample)
SA (1) SA515361092B1 (enExample)
WO (2) WO2014150660A1 (enExample)
ZA (1) ZA201507661B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114126587A (zh) * 2019-07-08 2022-03-01 株式会社Moresco 用于制备微型乳剂的组合物、微型乳剂、它们的制造方法、以及微型乳剂的应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702930A (en) 2012-06-28 2017-05-26 Mcneil Ppc Inc Racecadotril liquid compositions
US9114171B2 (en) * 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
US9801819B2 (en) 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
US10039712B2 (en) 2012-06-28 2018-08-07 Johnson & Johnson Consumer Inc. Racecadotril lipid compositions
EP3086777A1 (en) * 2013-12-23 2016-11-02 Johnson & Johnson Consumer Inc. Racecadotril compositions
EP3331520A1 (en) * 2015-08-07 2018-06-13 Johnson & Johnson Consumer Inc. Methods of treatment using cadotril compositions
RU2745888C2 (ru) * 2016-08-23 2021-04-02 Джонсон энд Джонсон Консьюмер Инк. Новая улучшенная композиция рацекадотрила
EP3716954A1 (en) 2017-11-27 2020-10-07 Umecrine Cognition AB Pharmaceutical formulation of 3 -ethynyl-3 -hydroxyandrostan-17-one oxime
US20210378970A1 (en) * 2018-02-26 2021-12-09 R.P. Scherer Technologies, Llc Pharmaceutical dosage form for an emulsion of simethicone and loperamide
WO2022090490A1 (en) * 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease
WO2025212856A1 (en) * 2024-04-05 2025-10-09 The Board Of Regents Of The University Of Texas System Microemulsion formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101442990A (zh) * 2006-05-15 2009-05-27 生物计划公司 消旋卡多曲的新型给药形式
WO2014005032A1 (en) * 2012-06-28 2014-01-03 Mcneil-Ppc, Inc. Racecadotril lipid compositions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
FR2623498B1 (fr) 1987-11-24 1990-04-06 Bioprojet Soc Civ Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques
US5136076A (en) 1987-11-24 1992-08-04 Societe Civile Bioprojet Process for the preparation of amino acid-derived enatiomeric compounds
SE9503143D0 (sv) * 1995-09-12 1995-09-12 Astra Ab New preparation
US20020028248A1 (en) 1996-03-14 2002-03-07 Takayuki Tsukada Rapid-release microdispersible ecadotril preparation
WO1998040051A1 (en) 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
GB0015490D0 (en) 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
ES2247163T3 (es) 2000-06-23 2006-03-01 Bioprojet Formulacion en polvo seca que comprende racedotril.
EP1563848A1 (en) 2004-02-12 2005-08-17 Bioprojet New combinations of an anti-emetic agent and an enkephalinase inhibitor
CN101103960B (zh) 2006-07-14 2010-12-08 海南盛科生命科学研究院 一种含有消旋卡多曲的干混悬剂及其制备方法
CN101264065A (zh) 2008-04-18 2008-09-17 盐城苏海制药有限公司 消旋卡多曲滴丸及其制备方法
WO2011002702A1 (en) 2009-06-29 2011-01-06 Mcneil-Ppc, Inc. Pharmaceutical tablet containing a liquid filled capsule
CN102018707A (zh) * 2010-11-29 2011-04-20 昆明邦宇制药有限公司 一种治疗腹泻的药物组合物及其制剂
EP2462922A1 (en) 2010-12-10 2012-06-13 Bioprojet New form of administration of enkephalinase inhibitor
CN102133186B (zh) 2011-03-18 2012-08-01 海南美大制药有限公司 一种消旋卡多曲脂质体固体制剂
CN102327234B (zh) 2011-09-28 2017-04-12 海南康芝药业股份有限公司 一种消旋卡多曲干混悬剂
US9801819B2 (en) 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
NZ702930A (en) 2012-06-28 2017-05-26 Mcneil Ppc Inc Racecadotril liquid compositions
US9114171B2 (en) 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
EP2749270B1 (en) 2012-12-26 2018-01-17 ILKO Ilaç Sanayi ve Ticaret A.S. Racecadotril and pharmaceutical compositions thereof
EP3331520A1 (en) 2015-08-07 2018-06-13 Johnson & Johnson Consumer Inc. Methods of treatment using cadotril compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101442990A (zh) * 2006-05-15 2009-05-27 生物计划公司 消旋卡多曲的新型给药形式
WO2014005032A1 (en) * 2012-06-28 2014-01-03 Mcneil-Ppc, Inc. Racecadotril lipid compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOHN B. CANNO: "Strategies to Formulate Lipid-based Drug Delivery Systems", 《AMERICAN PHARMACEUTICAL REVIEW》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114126587A (zh) * 2019-07-08 2022-03-01 株式会社Moresco 用于制备微型乳剂的组合物、微型乳剂、它们的制造方法、以及微型乳剂的应用
CN114126587B (zh) * 2019-07-08 2023-11-28 株式会社Moresco 用于制备微型乳剂的组合物、微型乳剂、它们的制造方法、以及微型乳剂的应用

Also Published As

Publication number Publication date
WO2015100234A1 (en) 2015-07-02
RU2662069C2 (ru) 2018-07-23
US20140271832A1 (en) 2014-09-18
CA2907195A1 (en) 2014-09-25
IL241065A0 (en) 2015-11-30
MX2016008390A (es) 2017-01-11
US20140275246A1 (en) 2014-09-18
MX2015012345A (es) 2017-03-27
RU2015144013A (ru) 2017-04-28
BR112015023387A2 (pt) 2017-07-18
WO2014150660A1 (en) 2014-09-25
PH12015502014A1 (en) 2016-01-11
RU2016129907A (ru) 2018-01-30
AU2014235733A1 (en) 2015-09-24
SA515361092B1 (ar) 2018-01-17
RU2016129907A3 (enExample) 2018-09-13
AU2014370027A1 (en) 2016-07-07
US9801819B2 (en) 2017-10-31
EP2968138B1 (en) 2018-08-15
EP2968138A1 (en) 2016-01-20
JP2016512828A (ja) 2016-05-09
ZA201507661B (en) 2017-09-27
US20160331684A9 (en) 2016-11-17
CA2934816A1 (en) 2015-07-02
US9636300B2 (en) 2017-05-02
KR20160101167A (ko) 2016-08-24
AU2014235733B2 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
US9636300B2 (en) Racecadotril lipid compositions
CN104411299B (zh) 消旋卡多曲类脂组合物
CN100367951C (zh) 丁苯酞静脉乳剂及其应用
EP2062571A1 (en) Self-emulsifying pharmaceutical composition with enhanced bioavailability
KR20010093281A (ko) 자발분산성 n-벤조일-스타우로스포린 조성물
EP3955894A1 (en) Self-emulsifying drug delivery systems for delivery of lipophilic compounds
US20150342882A1 (en) Methods of treatment using cadotril compositions
CN105848643A (zh) 消旋卡多曲组合物
CN100556407C (zh) 桂利嗪自乳化胶囊及其制备方法
HK1208178B (en) Racecadotril lipid compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160113